MNOV - MediciNova, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.1400 |
| Open | 2.1600 |
| Bid | 2.1000 x 900 |
| Ask | 2.1700 x 1300 |
| Day's Range | 2.1500 - 2.1650 |
| 52 Week Range | 1.8900 - 2.7700 |
| Volume | |
| Avg. Volume | 19,819 |
| Market Cap | 105.456M |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2800 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.50 |
Fair Value
Related Research
Zacks Small Cap ResearchMNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Positive Attributes Make MediciNova a Compelling Buying Opportunity MediciNova, Inc. (NASDAQ:MNOV) is a biopharmaceutical company focused on developing small molecule therapies for treating a range of diseases with high unmet medical need. With the biotechnology sector continuing to face a number of headwinds, we
GlobeNewswireMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
LA JOLLA, Calif., May 14, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for patients diagnosed with a microorganism infection. Once issued, the patent maturing from this allowed patent applicatio
- GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
LA JOLLA, Calif., April 30, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of advanced nonalcoholic steatohepatitis (NASH). Once issued, the patent maturing from this allo
Simply Wall St.We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast)
- Zacks Small Cap Research
MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update GBM Trial Fully Enrolled On January 12, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced that the Phase 2 trial of MN-166 (ibudilast) in combination with temozolomide (TMZ) for the treatment of glioblastoma (GBM) is fully enrolled ( NCT03782415 ). This is a two-part trial taking place at Dana-Farber Cancer Institute;
- GlobeNewswire
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
LA JOLLA, Calif., Feb. 20, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia, PhD, Scientific Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at Cleveland Clinic and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Ca
- GlobeNewswire
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
LA JOLLA, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, the l
- GlobeNewswire
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
LA JOLLA, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2b clinical trial evaluating MN-166 (ibudilast) for the treatment of alcohol use disorder (AUD) has completed enrollment. This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The NIAAA R01 research funding
- GlobeNewswire
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and TherapeuticsLA JOLLA, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial evaluating MN-166 (ibudilast) in recurrent and newly diagnosed glioblastoma conducted at Dana-Farber Cancer Inst
- GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
LA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of scleroderma and/or systemic sclerosis. Once issued,
- GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
LA JOLLA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Brazilian Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hype
- GlobeNewswire
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteersLA JOLLA, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a Phase I clinical trial to evaluate MN-166 (ibudilast) 10 mg intravenous (IV) infusion in healthy volunteers (HV) has been completed. The trial re
- GlobeNewswire
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabet
- GlobeNewswire
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
LA JOLLA, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a secondary analysis of a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in The American Journal of Drug and Alcohol Abuse. The clinical trial was a collaborative effort between MediciNova and Dr. Lara Ray
Insider Monkey13 Best Biotech Penny Stocks To Buy Now
In this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […]
- Zacks Small Cap Research
MNOV: Well Financed to Get Through Tough Market Conditions…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Well-Financed to Advance the Pipeline MediciNova, Inc. (NASDAQ:MNOV) is developing MN-166 and MN-001 for a number of indications with high unmet medical needs. Importantly, with $62.5 million of cash + CDs and an operating cash burn of about $12 million per year, the company is well-financed to advance both
- GlobeNewswire
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022. Yuichi Iwaki, MD, PhD, President and Chief Executive Of
- GlobeNewswire
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a
BenzingaMediciNova Poised To Receive Canadian Patents For Cholesterol Candidates
MediciNova Inc (NASDAQ: MNOV) received a Notice of Allowance Canadian patent covering MN-001 (tipelukast) and MN-002 (a significant metabolite of MN-001) for hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover the use of MN-001 or MN-002 for reducing triglyceride blood level, total cholesterol blood level, and low-density lipoprotein (L
- GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
LA JOLLA, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyp
- Zacks Small Cap Research
MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Phase 2 Trial of MN-001 in Patients with NAFLD, Type 2 Diabetes, and Hypertriglyceridemia Underway On July 26, 2022, MediciNova, Inc. (NASDAQ:MNOV) announced the initiation of a Phase 2 trial to evaluate MN-166 in patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), and
- GlobeNewswire
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
LA JOLLA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to participate in RECLAIM (Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial), a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, th
- GlobeNewswire
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
LA JOLLA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Serum Lipid Panel by Tipelukast (MN-001) in Type 2 Diabetes and NAFLD Patients" has been accepted and selected for poster presentation at the International Diabetes Federation (IDF) 2022 Congress to be held December 5 - 8, 2022.
- GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
LA JOLLA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Korean Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of fibrosis which includes a wide range of fibrotic